欧洲医学肿瘤学会专家共识声明：治疗EGFR阳性非小细胞肺癌

FutureONCOLOGYPlain Language Summary of PublicationPlain language summary and patientperspective of the European Society forMedical Oncology expert consensusstatements on treating EGFR-positivenon-small-cell lung cancerRachel Jenkins*,Joanne Walker2 and Upal Basu Roy3'Future Science Group,London,UK:"Becaris Publishing Ltd,Royston,UK:3LUNGevity Foundation,Chicago,IL,USA*Author for correspondenceFirst draft submitted:5 December 2022;Accepted for publication:17 February 2023;Published online:20 March 2023SummaryHow to say(double click sound iconto play sound)...What is this summary about?This article provides a plain language summary and patient perspective of.Osimertinib:OH-sih-MER-tih-niba new set of recommendations made by the European Society for MedicalOncology(ESMO for short).These recommendations are also called expertTyrosine kinase inhibitors:consensus statements.They cover the management of people with a typeTY-ruh-seen KY-nays in-HIH-bih-tersof lung cancer called epidermal growth factor receptor-positive non-Pronunciations taken from the National Cancer Institute.small-cell lung cancer (EGFR-positive NSCLC for short).Dictionary of Cancer TermsWhy were the recommendations developed?The ESMO Clinical Practice Guidelines are used by healthcare professionals when treating people with cancer,but they don't necessarily have all the information healthcare professionals need to make decisions forwith people with EGFR-positive NSCLC.So,in 2021,32 healthcare professionals who are experts in treatingpeople with EGFR-positive NSCLC worked together to produce recommendations to fill these gaps aboutEGFR-positive NSCLC.This was called a consensus-building process and it also included patient advocates.What recommendations did they make?The experts discussed four main topics including how people with different stages of EGFR-positive NSCLC arediagnosed and treated,and how clinical studies are done.They reviewed the scientific information that exists on thesesubjects.They reached an agreement and developed the recommendations that are summarized here.Who is this article for?This summary may be helpful for people with EGFR-mutant NSCLC who are considering treatment options,their families,patient advocates(representatives),caregivers and healthcare professionals.Where can I find the original article on which this summary is based?You can read the original article for a fee at the below link:Futurehttps://www.annalsofoncology.org/article/S0923-7534(22)00112-0/fulltextMedicine Paort of10.2217/fon-2022-1213©2023 The AuthorsFuture Oncol.(Epub ahead of print)t5SN1479-6694